Literature DB >> 31047960

Deleterious Effects of Higher Body Mass Index on Subjective and Objective Measures of Chemotherapy-Induced Peripheral Neuropathy in Cancer Survivors.

Iva Petrovchich1, Kord M Kober1, Laura Wagner1, Steven M Paul1, Gary Abrams2, Margaret A Chesney2, Kimberly Topp2, Betty Smoot2, Mark Schumacher2, Yvette P Conley3, Marilyn Hammer4, Jon D Levine2, Christine Miaskowski5.   

Abstract

CONTEXT: Recent, albeit, limited evidence suggests that body mass index (BMI) may be a modifiable risk factor to reduce the deleterious effects of chemotherapy-induced peripheral neuropathy (CIPN) in cancer survivors.
OBJECTIVES: To evaluate for differences in demographic, clinical, pain, sensation, and balance characteristics among three BMI groups. We hypothesized that as BMI increased, survivors would report higher pain intensity scores and have significant decrements in measures of sensation and balance.
METHODS: A total of 416 survivors with CIPN were evaluated using subjective and objective measures of CIPN. Survivors were divided into three BMI groups (i.e., normal weight, overweight, and obese). Differences among the BMI groups were evaluated using parametric and nonparametric statistics.
RESULTS: Of the 416 survivors, 45.4% were normal weight, 32.5% were overweight, and 22.1% were obese. Compared with the normal-weight group, survivors in the other two groups had lower functional status scores, a higher comorbidity burden, higher pain intensity scores, and higher interference scores. In addition, compared with the normal-weight group, survivors in the other two BMI groups had significantly worse balance scores.
CONCLUSION: Our findings support the hypothesis that as BMI increased, pain sensation and balance characteristics worsened. Our findings suggest that nutritional counseling as well as exercise and weight management programs in survivors with CIPN may improve these clinically important problems.
Copyright © 2019 American Academy of Hospice and Palliative Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Chemotherapy; balance; body mass index; cancer survivor; peripheral neuropathy; platinum; taxane

Mesh:

Substances:

Year:  2019        PMID: 31047960      PMCID: PMC6679783          DOI: 10.1016/j.jpainsymman.2019.04.029

Source DB:  PubMed          Journal:  J Pain Symptom Manage        ISSN: 0885-3924            Impact factor:   5.576


  49 in total

1.  Moderate chronic pain, weight and dietary intake in African-American adult patients with sickle cell disease.

Authors:  Jennifer J Pells; Katherine E Presnell; Christopher L Edwards; Mary Wood; Myleme O Harrison; Laura DeCastro; Stephanie Johnson; Miriam Feliu; Stephanie Canada; Jude C Jonassaint; Camela Barker; Brittani Leach-Beale; Markece J Mathis; Katherine Applegate; Anita Holmes; Goldie Byrd; Elwood Robinson
Journal:  J Natl Med Assoc       Date:  2005-12       Impact factor: 1.798

Review 2.  Obesity, inflammation, and the gut microbiota.

Authors:  Amanda J Cox; Nicholas P West; Allan W Cripps
Journal:  Lancet Diabetes Endocrinol       Date:  2014-07-22       Impact factor: 32.069

Review 3.  Knee osteoarthritis phenotypes and their relevance for outcomes: a systematic review.

Authors:  L A Deveza; L Melo; T P Yamato; K Mills; V Ravi; D J Hunter
Journal:  Osteoarthritis Cartilage       Date:  2017-08-25       Impact factor: 6.576

4.  Assessment of pain quality in chronic neuropathic and nociceptive pain clinical trials with the Neuropathic Pain Scale.

Authors:  Mark P Jensen; Robert H Dworkin; Arnold R Gammaitoni; David O Olaleye; Napoleon Oleka; Bradley S Galer
Journal:  J Pain       Date:  2005-02       Impact factor: 5.820

5.  The Association of Chemotherapy-Induced Peripheral Neuropathy Symptoms and the Risk of Falling.

Authors:  Noah A Kolb; A Gordon Smith; J Robinson Singleton; Susan L Beck; Gregory J Stoddard; Summer Brown; Kathi Mooney
Journal:  JAMA Neurol       Date:  2016-07-01       Impact factor: 18.302

Review 6.  New diagnostic tests for diabetic distal symmetric polyneuropathy.

Authors:  Nikolaos Papanas; Dan Ziegler
Journal:  J Diabetes Complications       Date:  2009-11-06       Impact factor: 2.852

7.  Effects of exercise during chemotherapy on chemotherapy-induced peripheral neuropathy: a multicenter, randomized controlled trial.

Authors:  Ian R Kleckner; Charles Kamen; Jennifer S Gewandter; Nimish A Mohile; Charles E Heckler; Eva Culakova; Chunkit Fung; Michelle C Janelsins; Matthew Asare; Po-Ju Lin; Pavan S Reddy; Jeffrey Giguere; Jeffrey Berenberg; Shelli R Kesler; Karen M Mustian
Journal:  Support Care Cancer       Date:  2017-12-14       Impact factor: 3.603

Review 8.  Pain Experience and Perception in the Obese Subject Systematic Review (Revised Version).

Authors:  Bart Torensma; Irene Thomassen; Monique van Velzen; Bastiaan Alexander In 't Veld
Journal:  Obes Surg       Date:  2016-03       Impact factor: 4.129

9.  Neuropathy is not associated with clinical outcomes in patients receiving adjuvant taxane-containing therapy for operable breast cancer.

Authors:  Bryan P Schneider; Fengmin Zhao; Molin Wang; Vered Stearns; Silvana Martino; Vicky Jones; Edith A Perez; Tom Saphner; Antonio C Wolff; George W Sledge; William C Wood; Nancy E Davidson; Joseph A Sparano
Journal:  J Clin Oncol       Date:  2012-07-30       Impact factor: 44.544

Review 10.  Long-Term Effects, Pathophysiological Mechanisms, and Risk Factors of Chemotherapy-Induced Peripheral Neuropathies: A Comprehensive Literature Review.

Authors:  Nicolas Kerckhove; Aurore Collin; Sakahlé Condé; Carine Chaleteix; Denis Pezet; David Balayssac
Journal:  Front Pharmacol       Date:  2017-02-24       Impact factor: 5.810

View more
  7 in total

Review 1.  The Physical Consequences of Chemotherapy-Induced Peripheral Neuropathy.

Authors:  Cindy S Tofthagen; Andrea L Cheville; Charles L Loprinzi
Journal:  Curr Oncol Rep       Date:  2020-04-22       Impact factor: 5.075

2.  Second messengers mediating high-molecular-weight hyaluronan-induced antihyperalgesia in rats with chemotherapy-induced peripheral neuropathy.

Authors:  Ivan J M Bonet; Larissa Staurengo-Ferrari; Dionéia Araldi; Paul G Green; Jon D Levine
Journal:  Pain       Date:  2021-12-06       Impact factor: 7.926

3.  Neuroendocrine Stress Axis-Dependence of Duloxetine Analgesia (Anti-Hyperalgesia) in Chemotherapy-Induced Peripheral Neuropathy.

Authors:  Larissa Staurengo-Ferrari; Ivan J M Bonet; Dioneia Araldi; Paul G Green; Jon D Levine
Journal:  J Neurosci       Date:  2021-12-08       Impact factor: 6.709

4.  Sexual dimorphism in the contribution of neuroendocrine stress axes to oxaliplatin-induced painful peripheral neuropathy.

Authors:  Larissa Staurengo-Ferrari; Paul G Green; Dionéia Araldi; Luiz F Ferrari; Christine Miaskowski; Jon D Levine
Journal:  Pain       Date:  2021-03-01       Impact factor: 7.926

5.  Exploring the impact of a decision support algorithm to improve clinicians' chemotherapy-induced peripheral neuropathy assessment and management practices: a two-phase, longitudinal study.

Authors:  Robert Knoerl; Emanuele Mazzola; Fangxin Hong; Elahe Salehi; Nadine McCleary; Jennifer Ligibel; Kaitlen Reyes; Donna L Berry
Journal:  BMC Cancer       Date:  2021-03-06       Impact factor: 4.430

Review 6.  Diet/Nutrition: Ready to Transition from a Cancer Recurrence/Prevention Strategy to a Chronic Pain Management Modality for Cancer Survivors?

Authors:  Sevilay Tümkaya Yılmaz; Anneleen Malfliet; Ömer Elma; Tom Deliens; Jo Nijs; Peter Clarys; An De Groef; Iris Coppieters
Journal:  J Clin Med       Date:  2022-01-27       Impact factor: 4.241

7.  Predictors for development of oxaliplatin-induced peripheral neuropathy in cancer patients as determined by ordered logistic regression analysis.

Authors:  Yuko Kanbayashi; Takeshi Ishikawa; Yoshiaki Kuriu; Eigo Otsuji; Koichi Takayama
Journal:  PLoS One       Date:  2022-09-29       Impact factor: 3.752

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.